Short-Term Intraocular Pressure Changes After Intravitreal Aflibercept 8&#xa0;mg via Prefilled Syringe

Macular Diseases

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study

Ophthalmol Ther

Volpe G, Bonanata M, Peyla A, Ruscitti L, Eggarter V, Pache M, Paris A, Menghini M, Grimaldi G

doi: 10.1007/s40123-026-01431-z

Macular Diseases

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Ophthalmology

Do DV, Wykoff CC, Sivaprasad S, Brown DM, Boyer DS, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Cheng Y, Bhore R, Bai Z, Schmidt-Ott U, Schmelter T, Schulze A, Hasanbasic Z, Morgan-Warren PJ, Zhang X, Hirshberg B, Yancopoulos GD, PHOTON investigators

doi: 10.1016/j.ophtha.2025.10.028

Macular Diseases

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

Br J Ophthalmol

Chalkiadaki E, Sim YS, Williams O, Elder L, Addison PK, Hamilton RD, Nicholson L, Sivaprasad S, Heng LZ

doi: 10.1136/bjo-2025-328893

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics

Ophthalmol Retina

Gale RP, Loewenstein A, Zhang X, Leal S, Machewitz T, Sivaprasad S, Wong DT, Zeitz O, Korobelnik JF, PULSAR study investigators

doi: 10.1016/j.oret.2026.02.020

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular Diseases

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Retina

Lee C, Karunainathan MG, Zohalinejad KD, Mæng MO, Fabrin NW, Yde SK, Wykoff CC, Abildgaard SK, Vorum H, Subhi Y, Ørskov M, Cehofski LJ

doi: 10.1097/IAE.0000000000004888

Further Publications

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries

Ophthalmol Retina

Lakhani M, Popovic MM, Al-Ani A, Kundapur D, Gholamian T, Chaudry E, Nanji K, Patil N, Feo A, Sadda S, Sarraf D, Ip MS, Kertes PJ, Muni RH, Adatia F, Damji KF, Chaudhary V, Hurley BR

doi: 10.1016/j.oret.2025.10.019

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Related content

Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in nAMD in Subgroups Defined by Baseline Characteristics

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Real-World Outcomes after Switch to Aflibercept 8 mg in Neovascular AMD: Twelve Months Follow-up on 654 Eyes

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report